Sponsored by
News
Oral vaccine for UTI could provide an alternative to antibiotics
Recurrent Urinary Tract Infections (UTIs) can be prevented for up to nine years in more than half of people given an oral spray-based vaccine and is a potential alternative to antibiotic treatments, finds research. Initial results from the first long-term follow-up study of the safety and effectiveness of the MV140 vaccine for recurrent UTIs were presented at the European Association of Urology (EAU) Congress in Paris. They show that in both men and women with
recurrent UTIs, 54% of study participants remained UTI-free for nine years after the vaccine, with no notable side effects reported. Full results of the study are expected to be published by the end of 2024. UTIs are the most common bacterial infection. They are experienced by half of all women and one in five men and can be painful and uncomfortable. Recurrent infections, needing short-term antibiotic treatment, develop in between 20 to 30 percent of cases. With antibiotic resistant UTIs now on the rise and drugs becoming less effective, new ways of preventing and treating these infections are needed. Carried out by clinicians at the UK’s Royal Berkshire Hospital, this long-term follow-up looked at the safety and efficacy of the MV140 vaccine in 89 patients originally treated privately at The Urology Partnership Reading. Dr. Bob Yang, Consultant Urologist at the Royal
Berkshire NHS Foundation Trust, who co-led the research, said “Before having the vaccine, all our participants suffered with recurrent UTIs and, for
HCWs to receive one-off payments
The government will provide funding for over 27,000 more healthcare workers in England to receive two one-off payments - worth at least £1,655 and up to £3,000.
Community nurses, sexual health
workers, speech and language therapists, physiotherapists and other crucial frontline workers are all set to benefit. Organisations will receive funding for these payments over the coming months. Forming part of the wider NHS pay deal, one of the payments was specifically intended to recognise the sustained pressure facing the health service and the extraordinary efforts of staff in tackling waiting lists. Health and Social Care Secretary Victoria
many women, these can be difficult to treat. Nine years after first receiving this new UTI vaccine, around half of participants remained infection free. Overall, this vaccine is safe in the long term and our participants reported having fewer UTIs that were less severe. Many of those who did get a UTI told us that simply drinking plenty of water was enough to treat it. “This is a very easy vaccine to administer and could be given by GPs as a three-month course. Many of our participants told us that having the vaccine restored their quality of life. While we’re yet to look at the effect of this vaccine in different patient groups, this follow-up data suggests it could be a game changer for UTI prevention, if it’s offered widely, reducing the need for antibiotic treatments.”
Atkins said: “I hugely value the hard work of all our healthcare staff, and those working in non-NHS organisations offer vital support to patients. I want to ensure that eligible staff receive these payments, which is why we chose to deliver this funding and why we have taken the decision to relax the financial eligibility criteria employers must meet. It will ensure that hardworking staff and the organisations they work for can fully benefit from the NHS pay deal.”
Last year, more than one million staff on the Agenda for Change contract - including nurses, paramedics, 999 call handlers, midwives, security guards and cleaners - received two one-off payments alongside a 5% pay rise.
Disinfect with Swabsticks!
The single-use PT1 biocide swabstick is a ready to use device containing 2% (w/w) Chlorhexidine gluconate and 70% (v/v) Isopropyl alcohol
+ Unique 2-sided pre-saturated applicator for interdigital areas and skin folds
+ Available via the NHSSC (DMK060)
Write to us at
contact@pdi-emea.com to request your FREE samples W:
pdi-intl.com
T: + 44 (0) 8081 697 945 PDI International May 2024 I
www.clinicalservicesjournal.com 11
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
